Pt(IV) prodrug nanoparticle NP2 potentiates chemo-immunotherapy for nasopharyngeal carcinoma via cGAS-STING activation

Current first-line cisplatin-based chemo-immunotherapy for advanced nasopharyngeal carcinoma (NPC) faces significant limitations, including off-target toxicity, acquired platinum resistance, and an immunosuppressive tumor microenvironment (TME). These challenges often lead to suboptimal patient outcomes and disease progression. There is an urgent need for novel strategies that can enhance therapeutic efficacy while mitigating adverse effects. This study addresses this gap by exploring the potential of targeting DNA repair mechanisms and activating innate immune pathways, specifically cGAS-STING, to improve NPC treatment.

Researchers developed NP2, a novel Pt(IV) prodrug nanoparticle, designed to target DNA repair in cancer cells. They investigated its therapeutic potential in both in vitro NPC cell line models and in vivo mouse models of nasopharyngeal carcinoma. The study assessed NP2's ability to inhibit DNA repair, activate the cGAS-STING pathway, and enhance the efficacy of standard chemo-immunotherapy regimens. Key endpoints included tumor growth inhibition, immune cell infiltration, and molecular pathway analysis using techniques such as Western blot, qPCR, and flow cytometry.

The Pt(IV) prodrug nanoparticle NP2 effectively delivered its payload, leading to targeted inhibition of DNA repair mechanisms within nasopharyngeal carcinoma (NPC) cells. This inhibition significantly sensitized the cancer cells to platinum-based chemotherapy. The study demonstrated that NP2 treatment, particularly when combined with chemotherapy, robustly activated the cGAS-STING pathway, resulting in enhanced type I interferon production crucial for anti-tumor immunity. In preclinical models, NP2 significantly potentiated the efficacy of chemo-immunotherapy, leading to improved tumor control and reduced tumor burden. This potentiation was attributed to both direct cytotoxic effects and the reprogramming of the immunosuppressive tumor microenvironment (TME) towards a more immune-responsive state, fostering enhanced anti-tumor immunity. The combination strategy effectively helped overcome platinum resistance and reduced off-target toxicity, addressing major limitations of current NPC treatments.

NP2 treatment, especially in combination with chemotherapy, robustly activated the cGAS-STING pathway, leading to increased type I interferon production and enhanced anti-tumor immunity.